🇺🇸 FDA
Patent

US 8822469

Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase

granted A61PA61P35/00A61P43/00

Quick answer

US patent 8822469 (Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase) held by Vertex Pharmaceuticals Incorporated expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Sep 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61P, A61P35/00, A61P43/00